Wedbush Reiterates Outperform on Black Diamond Therapeutic, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Black Diamond Therapeutic (NASDAQ:BDTX) and maintained a price target of $16.
August 07, 2024 | 2:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Black Diamond Therapeutic (NASDAQ:BDTX) and maintained a price target of $16.
The reiteration of an Outperform rating and the maintenance of a $16 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100